skip to main content

H.R. 3 (116th): Elijah E. Cummings Lower Drug Costs Now Act

Call or Write Congress

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Frank Pallone

Sponsor. Representative for New Jersey's 6th congressional district. Democrat.

Read Text »
Last Updated: Sep 8, 2020
Length: 320 pages
Sep 19, 2019
116th Congress (2019–2021)
Died in a previous Congress

This bill was introduced in a previous session of Congress and was passed by the House on December 12, 2019 but was never passed by the Senate.

Although this bill was not enacted, its provisions could have become law by being included in another bill. It is common for legislative text to be introduced concurrently in multiple bills (called companion bills), re-introduced in subsequent sessions of Congress in new bills, or added to larger bills (sometimes called omnibus bills).


106 Cosponsors (106 Democrats)


Position statements

What legislators are saying

Schakowsky Slams Trump for Sabotaging Seniors’ Health Care with a Prescription Drug Pricing Stunt
    — Rep. Janice “Jan” Schakowsky [D-IL9] (Co-sponsor) on Sep 25, 2020

Chairman Neal Statement on Trumps Empty Drug Pricing Order
    — Rep. Richard Neal [D-MA1] (Co-sponsor) on Sep 14, 2020

Congressman Griffiths Weekly E-Newsletter 10.16.20
    — Rep. Morgan Griffith [R-VA9] on Oct 16, 2020

More statements at ProPublica Represent...

What stakeholders are saying

R Street Institute estimates H.R. 3 will add $40.3 billion in new spending through 2029.
Lymphatic Education & Research Network (LE&RN) The Lymphatic Education & Research Network (LE&RN) is pleased that the Lymphedema Treatment Act (H.R. 1948) will be included in H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act of 2019. The Lymphedema Treatment Act is sponsored by Congressperson …


Sep 19, 2019

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Sep 25, 2019
Considered by Health

A committee held a hearing or business meeting about the bill.

Oct 17, 2019
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Oct 22, 2019
Considered by House Committee on Ways and Means

A committee held a hearing or business meeting about the bill.

Dec 12, 2019
Passed House (Senate next)

The bill was passed in a vote in the House. It goes to the Senate next.

Jan 29, 2020
Considered by House Committee on Homeland Security

A committee held a hearing or business meeting about the bill.

H.R. 3 (116th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number H.R. 3. This is the one from the 116th Congress.

This bill was introduced in the 116th Congress, which met from Jan 3, 2019 to Jan 3, 2021. Legislation not passed by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3 — 116th Congress: Elijah E. Cummings Lower Drug Costs Now Act.” 2019. November 27, 2022 <>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from, the official portal of the United States Congress. is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.